新闻
EGRX
--
0.00%
--
Argatroban市场2021年:最新行业趋势,增长,份额,规模和2026年预测研究报告以及主要国家/地区数据
Apr 13, 2021 (The Expresswire) -- Global “Argatroban Market" 2021-2026 Research Report provides key analysis on the market status of the Argatroban...
The Express Wire · 4天前
按制造商份额,价格,收入,毛利和至2025年的预测分列的2021年Argatroban市场规模报告
Apr 08, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Argatroban Market” report gives over all...
The Express Wire · 04/08 10:38
癌症微管蛋白抑制剂市场的近期趋势,深入分析,市场规模研究报告预测,到2027年
Apr 06, 2021 (Market Stats News via COMTEX) -- A new market research report titled "Global Cancer Tubulin Inhibitors Market 2021 Analysis and Industry...
Market Stats News · 04/06 20:56
迄今为止,SmarTrend Eagle Pharmaceut Call(EGRX)的回报率为9.8%
Apr 06, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on February 16th, 2021 at $45.63. In...
marketwatch.com · 04/06 05:37
Argatroban市场规模,价值和数量,按类型,应用,机会,趋势,份额,生产,进口,出口,消费,公司分析2021 – 2027
Apr 05, 2021 (The Expresswire) -- Global "Argatroban Market" report 2021 covers the present state of Market Share, CAGR, Revenue, Gross Market and the growth...
The Express Wire · 04/05 08:43
2024年全球Argatroban市场规模,份额,价值和竞争格局
Heraldkeepers · 04/02 03:48
Argatroban专业调查《 2021年全球市场增长,现状和前景研究报告》
Apr 01, 2021 (Heraldkeepers) -- Argatroban is a prescription medicine used to treat the symptoms of blood clots in adults (Thrombocytopenia) and Percutaneous...
Heraldkeepers · 04/01 10:24
迄今为止,SmarTrend Eagle Pharmaceut Call(EGRX)的回报率为6.9%
Mar 25, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Eagle Pharmaceut (NASDAQ:EGRX) on February 16th, 2021 at $45.63. In...
marketwatch.com · 03/25 18:03
2020年全球Alimta市场应用,按特定产品分列的市场规模,按地区分列的销售和收入2025
Mar 23, 2021 (CDN Newswire via Comtex) -- Global Alimta Market Growth 2020-2025 delivers an in-depth analysis of the market by value, by production capacity,...
CDN Newswire · 03/23 20:40
2020-2027年癌症微管蛋白抑制剂市场:Abraxis Biosciences,Agensys,Amgen
pune, India, Tue, 23 Mar 2021 04:09:55 / Comserve Inc. / -- Global Cancer Tubulin Inhibitors Market 2020 Size, forecast, and overview of current market...
Comserve · 03/23 08:12
Bendamustine Market 2021:截至2026年的主要主要公司业务状况,市场规模,增长和地理预测,以及主要国家/地区数据
Mar 18, 2021 (The Expresswire) -- Global “Bendamustine Market" 2021-2026 Research Report provides key analysis on the market status of the Bendamustine...
The Express Wire · 03/19 01:55
2021年全球苯达莫司汀市场规模按行业份额,最终用户需求,规模估算,增长因素,生产,行业统计,概述和至2026年的预测报告进行分析
The Express Wire · 03/10 05:27
到2026年按市场份额,行业统计数据,全球趋势评估,地域细分,业务挑战和投资机会分析的2021年阿格罗班市场规模
Mar 09, 2021 (The Expresswire) -- The report provides revenue of the globalArgatroban Market for the period 2016 and 2026, considering 2020 as the base year...
The Express Wire · 03/09 05:50
10-K:EAGLE PHARMACEUTICALS,INC。
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 03/05 14:09
DJ Eagle Pharmaceuticals,Inc.首席执行官Scott Tarriff谈2020年第四季度业绩-收益电话抄本> EGRX
Dow Jones · 03/02 21:07
8-K:鹰药业股份有限公司
(EDGAR Online via COMTEX) -- 0000827871 false 0000827871 2021-03-02 2021-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/02 20:07
Eagle Pharmaceuticals(EGRX)超过了第四季度的盈利预期
Zacks.com · 03/02 13:15
BRIEF-Eagle Pharmaceuticals Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.96
reuters.com · 03/02 12:05
Eagle Pharmaceuticals看到2021年调整后的研发支出为$ 26M- $ 3000万> EGRX
Eagle Pharmaceuticals Sees 2021 Adjusted R&D Spend $26M-$30M >EGRX
Dow Jones · 03/02 11:56
Eagle Pharmaceuticals 4Q Rev 4990万美元> EGRX
Eagle Pharmaceuticals 4Q Rev $49.9M >EGRX
Dow Jones · 03/02 11:52
微牛提供丰富的实时EGRX股票新闻,让你可以通过多个平台了解EGRX股票行情最新动态,这些免费的Eagle制药新闻可以帮助你做出明智投资。
EGRX 简况
Eagle Pharmaceuticals, Inc.是一家专业制药公司。该公司致力于开发和销售重症监护和肿瘤学领域的注射产品。该公司的产品组合包括EP-1101(阿加曲班)、Ryanodex(丹曲林钠)、多西他赛注射剂、非酒精制剂(非酒精多西他赛注射)、双氯芬酸 - 米索前列醇、EP-3101(盐酸苯达莫司汀注射液,即用型稀释液(RTD)浓缩液)和EP-3102(快速输注的苯达莫司汀RTD)(EP-3102 Bendeka)。它在开发的高级阶段的四个候选产品正在由美国食品和药物管理局(FDA)审查进行批准,包括EP-6101康吉奥即用型(RTU)比伐卢定、用于劳力性热射病的EP-4104(丹曲林钠)(EP-4104)和EP-5101(培美曲塞)(EP-5101)。其近期候选产品,Kangio是一种用于经皮腔内血管成形术的比伐卢定液体静脉注射产品。